Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Rituximab enhances chemotherapy for lymphoma.
• Maintenance rituximab benefits follicular and mantle cell lymphoma.
• The role of rituximab maintenance in diffuse large B-cell lymphoma (DLBCL) is unclear.

Purpose of the Study:

• To evaluate the efficacy of rituximab maintenance therapy in patients with DLBCL.
• To analyze survival outcomes including event-free survival (EFS), progression-free survival (PFS), and overall survival (OS).

Main Methods:

• Meta-analysis of 5 randomized controlled trials (RCTs) involving 1740 patients.
• Searched PubMed, MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials up to May 2016.
• Pooled hazard ratios (HRs) and relative risks (RRs) for time-to-event and other data.

Main Results:

• Rituximab maintenance significantly improved EFS (HR=0.80) and PFS (HR=0.72) compared to observation.
• No significant difference in overall survival (OS) was observed (HR=0.66).
• Subgroup analysis indicated improved EFS in male patients (HR=0.53) but not in female patients (HR=0.99).

Conclusions:

• Rituximab maintenance may offer survival advantages in DLBCL beyond standard chemotherapy, particularly for male patients.
• Potential for increased adverse events necessitates careful consideration of risks and benefits.
• Treatment decisions should balance survival gains against potential adverse events.